Patents Assigned to Novartis
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20150320880
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: May 20, 2015
    Publication date: November 12, 2015
    Applicant: NOVARTIS AG
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Christie P. Fanton, Catrin FINNER, Thomas HUBER, Kathy Miller, Siew Ho SCHLEYER, Kathrin Ulrike Tissot-Daguette
  • PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR
    Publication number: 20150320687
    Abstract: The present invention relates to a pharmaceutical composition comprising a) a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, b) one or more, e.g. 1, 2 or 3, surfactants with lubricant properties; c) one or more, e.g. 1, 2 or 3, dry binders with disintegrant properties; d) one or more, e.g. 1, 2 or 3, fillers, and e) one or more, e.g. 1, 2 or 3, disintegrants.
    Type: Application
    Filed: July 22, 2015
    Publication date: November 12, 2015
    Applicant: NOVARTIS AG
    Inventors: Hong Wen, Natrajan Kumaraperumal, Richard Nause
  • EQUIPMENT AND METHODS USED IN FOLDING AND IMPLANTING FOLDABLE LENSES IN THE EYE
    Publication number: 20150320593
    Abstract: Apparatuses, systems, and methods for folding an intraocular lens and inserting an intraocular lens into an eye are disclosed herein. In some instances, a system for folding an intraocular lens may include a folding pin, a guide pin rotatable about a longitudinal axis of the folding pin, and a stage laterally moveable relative to the folding pin. An intraocular lens may be secured between the folding pin and the guide pin and be folded onto the folding pin during rotation of the guide pin. A retention member may be used to hold the folded intraocular lens onto the folding pin.
    Type: Application
    Filed: May 8, 2014
    Publication date: November 12, 2015
    Applicant: Novartis AG
    Inventor: Neelesh Kunte
  • Methods of Using IL-1beta Compounds
    Publication number: 20150322148
    Abstract: This invention relates to methods employing IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    Type: Application
    Filed: July 28, 2015
    Publication date: November 12, 2015
    Applicant: Novartis AG
    Inventors: Philip Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
  • PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
    Publication number: 20150322060
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as a factor D inhibitor for the treatment of ophthalmic diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 12, 2015
    Applicant: NOVARTIS AG
    Inventors: Stefanie FLOHR, Ulrich HOMMEL, Edwige Liliane Jeanne LORTHIOIS, Jeurgen Klaus MAIBAUM, Nils OSTERMANN, Jean QUANCARD, Stefan Andreas RANDL, Olivier ROGEL, Anna VULPETTI
  • Liquid vaccines for multiple meningococcal serogroups
    Patent number: 9180204
    Abstract: Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilization. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: November 10, 2015
    Assignee: Novartis AG
    Inventor: Mario Contorni
  • Substituted pyridines for modulating the WNT signaling pathway
    Patent number: 9181235
    Abstract: The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R1, R2, R3 are as defined herein.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan, Lichun Shen, Rajender Reddy Leleti
  • Combination of lapatinib and trametinib
    Patent number: 9180129
    Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, or a pharmaceutically acceptable hydrate and/or salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: Tona M. Gilmer, Rakesh Kumar
  • Method of treatment of breast cancers over-expressing the SHP2 signature genes
    Patent number: 9181553
    Abstract: A method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS FORSCHUNGSSTIFTUNG ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Mohamed Bentires-Alj, Nicola Aceto, Michael Stadler
  • 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
    Patent number: 9181266
    Abstract: The present invention provides for compounds of formula (I): wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: Atwood Kim Cheung, Donovan Noel Chin, Jianmei Fan, Karen Marie Miller-Moslin, Michael David Shultz, Troy D Smith, Ronald Charles Tomlinson, Bakary-Barry Toure, Michael Scott Visser, Zhuoliang Chen
  • TEM8 antibodies, conjugates thereof, and their use
    Patent number: 9181340
    Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: November 10, 2015
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Novartis AG
    Inventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong, Mary Beth Hilton
  • N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors
    Patent number: 9181238
    Abstract: The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R2, R3, R4 and R5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: Shifeng Pan, John E. Tellew, Yongqin Wan, Yongping Xie, Xing Wang, Xia Wang, Shenlin Huang, Zuosheng Liu, Qiong Zhang
  • Surgical system having manifolds with integral pneumatic accumulators
    Patent number: 9180232
    Abstract: A surgical system having all of the various pneumatic control sub-systems or sub-manifolds integrally mounted on a common primary manifold. The various required control mechanisms such as valves are likewise integrally mounted to the common manifold and to the sub-manifolds. Within any or all of the sub-manifolds or primary manifolds, volumes of material not necessary for the operation of the manifold are carved or pocketed out and used to form integral accumulators for storing extra pressurized air. The volume of the accumulator can vary according to the pressurized air requirement of the particular manifold, or the overall pneumatic system.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: David L. Williams, Michael Bowman
  • Manufacturing process for pyrimidine derivatives
    Patent number: 9181215
    Abstract: The invention relates to new crystalline forms of processes for manufacturing a compound of formula 5, or a stereoisomer, tautomer or a salt thereof, wherein the substituents are as defined in the specification. The invention further relates to new manufacturing processes for specific solid forms of Compound A and its salts, to such solid forms and to use of said solid forms for the therapeutic treatment of warm-blooded animals.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: November 10, 2015
    Assignee: Novartis AG
    Inventors: Marilyn De La Cruz, Piotr H. Karpinski, Liladhar Murlidhar Waykole
  • KINASE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20150315150
    Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: July 13, 2015
    Publication date: November 5, 2015
    Applicant: Novartis AG
    Inventors: Matthew T. Burger, Wooseok Han, Jiong Lan, Gisele Nishiguchi
  • INFLUENZA VIRUS REASSORTMENT
    Publication number: 20150315548
    Abstract: New influenza donor strains for the production of reassortant influenza A viruses are provided.
    Type: Application
    Filed: December 2, 2013
    Publication date: November 5, 2015
    Applicants: Novartis AG, Synthetic Genomics Vaccines, Inc.
    Inventors: Peter MASON, Philip Ralph DORMITZER, Heidi TRUSHEIM, Pirada SUPHAPHIPHAT
  • PHARMACEUTICAL COMBINATION COMPRISING BINIMETINIB
    Publication number: 20150313902
    Abstract: A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 5, 2015
    Applicant: Novartis AG
    Inventors: Giordano CAPONIGRO, Scott DELACH, Shivang DOSHI, Thomas HORN-SPIROHN, Sunkyu KIM
  • Ring-substituted N-pyridinyl amides as kinase inhibitors
    Patent number: 9173883
    Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: November 3, 2015
    Assignee: NOVARTIS AG
    Inventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
  • Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
    Patent number: 9174985
    Abstract: The invention relates to salts of (7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid which are useful for treating diseases affected by the activation of the IP receptor, pharmaceutical compositions that contain the salts and processes for preparing the salts are also described.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: November 3, 2015
    Assignee: Novartis AG
    Inventors: Catherine Leblanc, Stephen Carl McKeown, Anett Perlberg, Nicola Tufilli
  • Monobactam organic compounds for the treatment of bacterial infections
    Patent number: 9174978
    Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: November 3, 2015
    Assignee: Novartis AG
    Inventors: Virender Singh Aulakh, Anthony Casarez, Xiaodong Lin, Mika Lindvall, Glenn McEnroe, Heinz Ernst Moser, Folkert Reck, Meiliana Tjandra, Robert Lowell Simmons, Aregahegn Yifru, Qingming Zhu